Citations

Clear

65 citation(s) found for "Tepper, SJ".

Zolmitriptan nasal spray in the acute treatment of cluster headache
Rapoport, Alan M. , Mathew, N. T., Silberstein, SD, Tepper, SJ , Sheftell, Fred D., Bigal, Marcelo E. , Dodick, David W.

Mayo Clinic

Neurology | August 27, 2007 | Volume: 69 | Issue: 9 | Pages: 821-826

10.1212/01.wnl.0000267886.85210.37 | PMID 17724283 Get It

Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
O’Dwyer, Peter J. , Haller, Daniel G. , Tepper, Joel E. , Ahnen, Dennis J. , Benson, Al B. , Rothenberg, Mace L., Petrelli, Nicholas J. , Lenz, Heinz‐Joseph, Diasio, Robert B. , Dubois, Raymond, Sargent, Daniel J. , Sloan, Jeff A. , Johnson, C. Daniel, Comis, Robert L., Eckhardt, Sabine , Hamilton, Stanley R. , O’Connell, Michael J. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | May 30, 2007 | Volume: 25 | Issue: 16 | Pages: 2313-2321

10.1200/jco.2006.08.6900 | PMID 17538178 Get It

Emerging technologies have greatly expanded our ability to detect, characterize, and treat colorectal cancer. The Coalition of Cancer Cooperative Groups convened a multidisciplinary panel, the Scientific Leadership Council in GI cancer, to discuss and advise on the priorities and opportunities to advance current and future approaches into the clinical arena to impact most rapidly the morbidity and mortality from this disease. The Council's recommendations for research priorities are the result of engagement of community and academic oncologists, patient advocacy groups, and other stakeholders including the pharmaceutical industry and governmental agencies. We detail some key prospects for investigation in the areas of colon cancer detection, prevention, and surgical and medical management. Many are in early or definitive clinical trials, and a focus on rapid accrual is urged. The implementation of biology-directed laboratory investigations, both in association with ongoing clinical trials and as a separate developmental strategy for targeted therapies, is supported as the route to individualized therapy.
Impact of T and N Stage and Treatment on Survival and Relapse in Adjuvant Rectal Cancer
Gunderson, Leonard L., Sargent, Daniel J. , Tepper, Joel E. , Begovič, Mirsada, Allmer, Cristine, Colangelo, Linda H., Smalley, Steven R., Haller, Daniel G. , Martenson, James A., Rich, Tyvin A. , Macdonald, John S., Willett, Christopher G. , Goldberg, Richard M. , Wolmark, Norman , O’Connell, Michael J. , Mayer, Robert J. , Ajani, Jaffer A. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | April 6, 2004 | Volume: 22 | Issue: 10 | Pages: 1785-1796

10.1200/jco.2004.08.173 | PMID 15067027 Get It

Purpose To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies. Patients and Methods Data were pooled from 3,791 eligible patients enrolled onto North Central Cancer Treatment Group (NCCTG) 79-47-51, NCCTG 86-47-51, US Gastrointestinal Intergroup 0114, National Surgical Adjuvant Breast and Bowel Project (NSABP) R01, and NSABP R02. Surgery alone (S) was the treatment arm in 179 patients. The remaining patients received adjuvant treatment as follows: irradiation (RT) alone (n = 281), RT + fluorouracil (FU) ± semustine bolus chemotherapy (CT; n = 779), RT + protracted venous infusion CT (n = 325), RT + FU ± leucovorin or levamisole bolus CT (n = 1,695), or CT alone (n = 532). Five-year follow-up was available in 94% of surviving patients, and 8-year follow-up, in 62%. Results Overall (OS) and disease-free survival were dependent on TN stage, NT stage, and treatment method. Even among N2 patients, T substage influenced 5-year OS (T1-2, 67%; T3, 44%; T4, 37%; P < .001). Three risk groups of patients were defined: (1) intermediate (T1-2/N1, T3/N0), (2) moderately high (T1-2/N2, T3/N1, T4/N0), and (3) high (T3/N2, T4/N1, T4/N2). For intermediate-risk patients, those receiving S plus CT had 5-year OS rates of 85% (T1-2/N1) and 84% (T3/N0), which was similar to results with S plus RT plus CT (T1-2/N1, 78% to 83%; T3/N0, 74% to 80%). For moderately high-risk lesions, 5-year OS ranged from 43% to 70% with S plus CT, and 44% to 80% with S plus RT plus CT. For high-risk lesions, 5-year OS ranged from 25% to 45% with S plus CT, and 29% to 57% with S plus RT plus CT. Conclusion Different treatment strategies may be indicated for intermediate-risk versus moderately high- or high-risk patients based on differential survival rates and rates of relapse. Use of trimodality treatment for all patients with intermediate-risk lesions may be excessive, since S plus CT resulted in 5-year OS of approximately 85%; however, 5-year disease-free survival rates with S plus CT were 78% (T1-2/N1) and 69%(T3/N0), indicating room for improvement.
Analysis of Surgical Salvage After Failure of Primary Therapy in Rectal Cancer: Results From Intergroup Study 0114
Tepper, Joel E. , Hollis, Donna, Niedzwiecki, Donna , Cooke, E. M., O’Connell, M. , Mayer, Robert J. , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | September 25, 2003 | Volume: 21 | Issue: 19 | Pages: 3623-3628

10.1200/jco.2003.03.018 | PMID 14512393 Get It

Purpose: Intergroup Study 0114 was designed to study the effect of various chemotherapy regimens delivered after potentially curative surgical resection of T3, T4, and/or node-positive rectal cancer. A subset analysis was undertaken to investigate the prevalence and influence of salvage therapy among patients with recurrent disease. Patients and Methods: Adjuvant therapy consisted of two cycles of fluorouracil (FU)-based chemotherapy followed by pelvic irradiation with chemotherapy and two more cycles of chemotherapy after radiation therapy. A total of 1,792 patients were entered onto the study and 1,696 were assessable. After a median of 8.9 years of follow-up, 715 patients (42%) had disease recurrence, and an additional 10% died without evidence of disease. Five hundred patients with follow-up information available had a single organ or single site of first recurrence (73.5% of all recurrences). Results: A total of 171 patients (34% of those with a single organ or single site of recurrence) had a potentially curative resection of the metastatic or locally recurrent disease. Single-site first recurrences in the liver, lung, or pelvis occurred in 448 patients (90% of the single-site recurrences), with 159 (35%) of these undergoing surgical resection for attempted cure. Overall survival differed significantly between the resected and nonresected groups (P < .0001), with overall 5-year probabilities of .27 and .06, respectively. Controlling for worst performance status at the time of recurrence does not alter this relationship. Patients who underwent salvage surgery had significantly increased survival (P < .001) for each site. Conclusion: Attempted surgical salvage of rectal cancer recurrence is performed commonly in the United States. The chance of a long-term cure with such intervention is approximately 27%.
Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control—Final Report of Intergroup 0114
Tepper, Joel E. , Niedzwiecki, Donna , Hollis, Donna, Benson, Al B. , Gunderson, L. L., Macdonald, J. S. , Martenson, James A., O’Connell, Maria , Cummings, B., Mayer, Robert J. , Niedzwiecki, Donna

Mayo Clinic

Journal of Clinical Oncology | July 27, 2002 | Volume: 20 | Issue: 7 | Pages: 1744-1750

10.1200/jco.2002.07.132 | PMID 11919230 Get It

PURPOSE: The gastrointestinal Intergroup studied postoperative adjuvant chemotherapy and radiation therapy in patients with T3/4 and N+ rectal cancer after potentially curative surgery to try to improve chemotherapy and to determine the risk of systemic and local failure. PATIENTS AND METHODS: All patients had a potentially curative surgical resection and were treated with two cycles of chemotherapy followed by chemoradiation therapy and two additional cycles of chemotherapy. Chemotherapy regimens were bolus fluorouracil (5-FU), 5-FU and leucovorin, 5-FU and levamisole, and 5-FU, leucovorin, and levamisole. Pelvic irradiation was given to a dose of 45 Gy to the whole pelvis and a boost to 50.4 to 54 Gy. RESULTS: One thousand six hundred ninety-five patients were entered and fully assessable, with a median follow-up of 7.4 years. There was no difference in overall survival (OS) or disease-free survival (DFS) by drug regimen. DFS and OS decreased between years 5 and 7 (from 54% to 50% and 64% to 56%, respectively), although recurrence-free rates had only a small decrease. The local recurrence rate was 14% (9% in low-risk [T1 to N2+] and 18% in high-risk patients [T3N+, T4N]). Overall, 7-year survival rates were 70% and 45% for the low-risk and high-risk groups, respectively. Males had a poorer overall survival rate than females. CONCLUSION: There is no advantage to leucovorin- or levamisole-containing regimens over bolus 5-FU alone in the adjuvant treatment of rectal cancer when combined with irradiation. Local and distant recurrence rates are still high, especially in T3N+ and T4 patients, even with full adjuvant chemoradiation therapy.